Metabolic response assessment with 18F-FDG-PET/CT is superior to modified RECIST for the evaluation of response to platinum-based doublet chemotherapy in malignant pleural mesothelioma
18F-FDG-PET/CT and mRESIST were used for tumour responsiveness evaluation in MPM. 29% of mRESIST stable disease (SD) patients were metabolic non-responders. Disease control rate was 93.9% and metabolic response rate was 71.9%. Progressive metabolic disease patients had lower time to progression. MRESIST stable disease (SD) patients should be further screened by 18F-FDG-PET/CT.